Heart failure & cardiomyopathies
Dilated Cardiomyopathy (DCM) Support: Cell Therapy and Circulatory Support for Dilated Cardiomyopathy Patients with Severe Ventricular Impairment
Authors' conclusion
This is the first trial to assess the safety and efficacy of cytokine and autologous intracoronary cell therapy with a procedural circulatory support device for patients with severe left ventricular impairment.
Study context
- Population
- Symptomatic DCM patients with left ventricular ejection fraction (LVEF) ≤ 35% despite optimal medical and device therapyplanned enrolment
- Participants
- 20 patients
- Outcome
- Change in LVEF from baseline
- Follow-up
- 3 months
Methodological detailsdesign paper, single-site, Secondary endpoints: change in LVEF at 12 months; change in exercise capacity, NYHA class, quality of life and NT-proBNP at 3 and 12 months, Safety endpoints: procedural safety and major adverse cardiac events at 3 and 12 months
- Design paper
- Single-site
- Secondary endpoints: change in LVEF at 12 months; change in exercise capacity, NYHA class, quality of life and NT-proBNP at 3 and 12 months
- Safety endpoints: procedural safety and major adverse cardiac events at 3 and 12 months
Original publication
DCM Support: Cell Therapy and Circulatory Support for Dilated Cardiomyopathy Patients with Severe Ventricular Impairment. ESC Heart Fail. Published 15 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →